Precision BioSciences
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 109
- Market Cap
- $70.2M
- Introduction
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC.
Increased Investment in Biotechnology: A Key Driver Transforming the Cas Nuclease Market 2024
The Cas nuclease market is forecasted to grow from $2.75 billion in 2023 to $6.56 billion by 2028 at a CAGR of 19.0%, driven by advancements in genome editing, increased biotechnology funding, and demand for personalized medicine.
Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Precision BioSciences announces financial results for Q3 2024, including approval for first Clinical Trial Application for PBGENE-HBV, initiation of phase 1 clinical program in Moldova, strengthened infectious disease capabilities, and expected cash runway into H2 2026. The company will host a virtual investor event on November 15, 2024, to discuss final PBGENE-HBV preclinical safety data and Phase 1 trial plans.
TG Therapeutics Reports Third Quarter 2024 Financial
TG Therapeutics reports Q3 2024 U.S. BRIUMVI net revenue of $83.3 million, raising full-year target to $300-$305 million. Conference call on Nov 4, 2024, at 8:30 AM ET to discuss financial results and recent developments.
Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate ...
Precision BioSciences receives CTA approval in Moldova for PBGENE-HBV, its in vivo gene editing program for chronic hepatitis B, aiming to eliminate cccDNA and inactivate integrated HBV DNA, with additional regulatory applications pending globally.
Six biotech companies advancing multiple sclerosis therapies
Multiple sclerosis (MS) is a chronic CNS disease with varied symptoms, caused by immune system attacks on myelin. Biotech companies like Biogen, Immunic Therapeutics, Kyverna Therapeutics, Progentos Therapeutics, TG Therapeutics, and Zenas BioPharma are developing new treatments, including BTK inhibitors, CAR-T therapies, and bispecific antibodies. The global MS drug market is expected to grow significantly, offering hope for more effective treatments for different forms of MS.
Data Roundup: September 2024 Features Updates in Ophthalmology Gene Therapy, CAR-T
In September 2024, CGTLive tracked promising data updates in CAR-T therapy for DLBCL, gene therapy for XLRP, and more. REGENXBIO's RGX-121 showed efficacy in MPSII, Biogen's nusinersen demonstrated efficacy in SMA at a higher dose, Allogeneic CAR-T azer-cel achieved CRs in DLBCL, Beacon's AGTC-501 maintained a favorable benefit-risk profile in XLRP, and Adicet Bio's ADI-001 indicated potential for autoimmune disease treatment.
Related Clinical Trials:
Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial
Precision BioSciences submitted Clinical Trial Applications for PBGENE-HBV, an in vivo gene editing program targeting chronic hepatitis B by eliminating cccDNA and inactivating integrated HBV DNA. Safety data and Phase 1 trial plans will be shared in November.
Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV
Precision BioSciences submits Clinical Trial Applications for Phase 1 study of PBGENE-HBV, an in vivo gene editing program targeting chronic hepatitis B by eliminating cccDNA and inactivating integrated HBV DNA, with data expected in 2025.
© Copyright 2025. All Rights Reserved by MedPath